Skip to Main Content

Author Details

Mark M Moasser
Helen Diller Family Comprehensive Cancer Center
1994
92
38
PMIDPaper TitleJournal TitlePublished Year
37815684A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer.Breast Cancer Res Treat2024
36759733A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF<sup>V600E</sup> colorectal tumors.Nat Cancer2023
36574481Molecular Pathways and Mechanisms of HER2 in Cancer Therapy.Clin Cancer Res2023
35108525Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers.Cell Rep2022
35731927Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions.Cancer Res2022
36923283A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.Cancer Res Commun2022
36070686Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling.Cell Rep2022
34872108Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models.Blood Adv2022
35108526Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling.Cell Rep2022
32603749Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC.J Invest Dermatol2021
33907275The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers.Sci Rep2021
33727342Proteomic Analysis of Src Family Kinase Phosphorylation States in Cancer Cells Suggests Deregulation of the Unique Domain.Mol Cancer Res2021
34489453Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid.NPJ Breast Cancer2021
34541033Loss of CDCP1 triggers FAK activation in detached prostate cancer cells.Am J Clin Exp Urol2021
33115654Expression and purification of active human kinases using Pichia pastoris as a general-purpose host.Protein Expr Purif2021
33152346Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A.Biochem Pharmacol2021
32593399HER family in cancer progression: From discovery to 2020 and beyond.Adv Cancer Res2020
32681091Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.Nat Commun2020
31160710Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities.Nat Cell Biol2019
29760043HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3.Cancer Res2018
30304684A Dimerization Function in the Intrinsically Disordered N-Terminal Region of Src.Cell Rep2018
29381433Targeting HER2 by Combination Therapies.J Clin Oncol2018
29511352Regulation of inside-out β1-integrin activation by CDCP1.Oncogene2018
28732202Retraction Notice to: An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 Pseudokinase.Cell Chem Biol2017
28760953CD318 is a ligand for CD6.Proc Natl Acad Sci U S A2017
28790114Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.Clin Cancer Res2017
26875185A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.Breast Cancer Res Treat2016
26860947Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin.Breast Cancer Res Treat2016
25609069HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive.Clin Cancer Res2015
26516700Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.Oncotarget2015
26438156A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers.Mol Cancer Ther2015
26204261The Evolving Landscape of HER2 Targeting in Breast Cancer.JAMA Oncol2015
25901353Disentangling multidimensional spatio-temporal data into their common and aberrant responses.PLoS One2015
25619841Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum.Oncogene2015
25605863Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.J Clin Oncol2015
24656791RETRACTED: An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase.Chem Biol2014
25017248A multilevel model of postmenopausal breast cancer incidence.Cancer Epidemiol Biomarkers Prev2014
24868026Two dimensions in targeting HER2.J Clin Oncol2014
24711549Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.J Clin Oncol2014
23243018Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells.Cancer Res2013
21706059A tumor-suppressing function in the epithelial adhesion protein Trask.Oncogene2012
22853430HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells.Biochem J2012
21189288Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling.Mol Cell Biol2011
21559459The structural features of Trask that mediate its anti-adhesive functions.PLoS One2011
21559012A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.Br J Cancer2011
21350003A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.Clin Cancer Res2011
21490433Trask phosphorylation defines the reverse mode of a phosphotyrosine signaling switch that underlies cell anchorage state.Cell Cycle2011
20371474Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.Sci Transl Med2010
20816829The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.Semin Cell Dev Biol2010
20179223HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.Clin Cancer Res2010
  • 1 - 50 of 92

Recommended Authors

Toni M Brand
University of Wisconsin School of Medicine and Public Health
Career Start Year 2011
Number of shared co-authors 3
Neil E Bhola
Zai Lab (US) LLC
Career Start Year 2006
Number of shared co-authors 6
Kris C Wood
Duke University
Career Start Year 2005
Number of shared co-authors 1
Jalna Meens
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2004
Number of shared co-authors 1
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 0
Christopher D Willey
University of Alabama at Birmingham
Career Start Year 2000
Number of shared co-authors 2
Ingrid A Mayer
Vanderbilt University Medical Center
Career Start Year 2000
Number of shared co-authors 3
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 1
Theresa M LaVallee
Parker Institute for Cancer Immunotherapy
Career Start Year 1996
Number of shared co-authors 2
John D Gordan
Quantitative Biosciences Institute (QBI), University of California San Francisco
Career Start Year 1996
Number of shared co-authors 11
Paul Haluska
Mayo Clinic
Career Start Year 1996
Number of shared co-authors 3
Steven J Isakoff
Massachusetts General Hospital
Career Start Year 1995
Number of shared co-authors 4
Krister Wennerberg
University of Copenhagen
Career Start Year 1994
Number of shared co-authors 1
Cristina E Tognon
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1993
Number of shared co-authors 1
Livio Trusolino
Candiolo Cancer Institute - FPO IRCCS
Career Start Year 1993
Number of shared co-authors 3
Barry R Davies
Oncology R&D
Career Start Year 1992
Number of shared co-authors 1
Senthil K Muthuswamy
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1992
Number of shared co-authors 2
Ron Bose
Washington University School of Medicine
Career Start Year 1991
Number of shared co-authors 3
Aykut Uren
Georgetown University Medical Center
Career Start Year 1991
Number of shared co-authors 1
Todd VanArsdale
Oncology Research Unit, Inc.
Career Start Year 1991
Number of shared co-authors 1
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 5
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 6
Joan Albanell
Hospital del Mar Research Institute
Career Start Year 1990
Number of shared co-authors 5
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 4
John A Copland
Mayo Clinic Jacksonville
Career Start Year 1982
Number of shared co-authors 1
Stanley Lipkowitz
Center for Cancer Research, National Cancer Institute
Career Start Year 1978
Number of shared co-authors 0
Christopher C Benz
Buck Institute for Research on Aging
Career Start Year 1977
Number of shared co-authors 9
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 16
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 3
Dennis J Slamon
David Geffen School of Medicine at university of california los angeles
Career Start Year 1973
Number of shared co-authors 5

Collaborators

Danislav S Spassov
Faculty of Pharmacy, Medical University of Sofia
Co-authored papers 13
Clifford A Hudis
Memorial Sloan Kettering Cancer Center, USA American Society of Clinical Oncology
Co-authored papers 12
Larry Norton
Memorial Sloan Kettering Cancer Center
Co-authored papers 10
Katherine S Panageas
Memorial Sloan Kettering Cancer Center
Co-authored papers 9
Natalia Jura
Cardiovascular Research Institute, University of California San Francisco
Co-authored papers 6
Kevan M Shokat
University of California San Francisco
Co-authored papers 5
Andrei Goga
University of California San Francisco
Co-authored papers 3
Laura J Van't Veer
University of California San Francisco
Co-authored papers 3
Denise M Wolf
University of California San Francisco
Co-authored papers 3
Michael R Freeman
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 2
Rahul Aggarwal
University of California San Francisco
Co-authored papers 2
Sungyong You
Cedars-Sinai Medical Center
Co-authored papers 2
Anne E Cress
University of Arizona Cancer Center, College of Medicine, University of Arizona
Co-authored papers 2
Frank McCormick
Frederick National Laboratory for Cancer Research
Co-authored papers 2
Sara Pollan
Cedars-Sinai Medical Center 8700 Beverly Blvd
Co-authored papers 2
Beatrice S Knudsen
University of Utah
Co-authored papers 2
Christina Yau
University of California San Francisco
Co-authored papers 2
Maria Rodriguez
Cedars-Sinai Medical Center 8700 Beverly Blvd
Co-authored papers 1
David E Shaw
Columbia University
Co-authored papers 1
Robert A Hiatt
University of California San Francisco
Co-authored papers 1
Jeremy F Reiter
Cardiovascular Research Institute
Co-authored papers 1
Rakesh Kumar
Rutgers New Jersey Medical School
Co-authored papers 1
Janice Barlow
Co-authored papers 1
Andrew J Dannenberg
Co-authored papers 1
William A Weiss
University of California san francisco
Co-authored papers 1
Jorge Silvio Gutkind
Moores Cancer Center, University of California San Diego
Co-authored papers 1
Kristel Kemper
Oncode Institute, The Netherlands Cancer Institute
Co-authored papers 1
Scott R VandenBerg
University of California san francisco
Co-authored papers 1
Jie J Zheng
Molecular Biology Institute, University of California los angeles
Co-authored papers 1
Marcia S Brose
Co-authored papers 1
Release 1.2